How India Exports Mefloquine to the World

As of March 2026, the FDA's Orange Book does not list any approved Abbreviated New Drug Applications (ANDAs) for mefloquine, indicating a lack of generic competition in the U.S. market. Mefloquine was designated as an orphan drug on July 22, 1987, for the treatment and prevention of chloroquine-resistant *Plasmodium falciparum* malaria; however, it has not received FDA approval for this indication.

Given the absence of approved ANDAs, Indian exporters aiming to enter the U.S. market must pursue the New Drug Application (NDA) pathway, which involves comprehensive clinical trials and a rigorous review process. The current exporter count from India suggests a competitive landscape, yet the U.S. market remains untapped due to regulatory barriers.

In the European Union, mefloquine is authorized for the treatment and prevention of malaria. The European Medicines Agency (EMA) conducted a Periodic Safety Update Report Single Assessment (PSUSA) for mefloquine, resulting in a variation to its marketing authorization in January 2018. (ema.europa.eu) The UK's Medicines and Healthcare products Regulatory Agency (MHRA) has issued strengthened warnings regarding neuropsychiatric side effects associated with mefloquine, advising against its use in individuals with a history of psychiatric disorders. (gov.uk)

Compliance with EU Good Manufacturing Practice (GMP) standards is mandatory for exporters targeting these markets. This includes adherence to stringent quality control measures and regular inspections to ensure product safety and efficacy.

Mefloquine is included in the World Health Organization's (WHO) Model List of Essential Medicines, underscoring its importance in global malaria treatment protocols. It is also listed in various pharmacopoeias, including the United States Pharmacopeia (USP), British Pharmacopoeia (BP), European Pharmacopoeia (EP), and Indian Pharmacopoeia (IP), ensuring standardized quality specifications across different regions.

In India, mefloquine is classified under Schedule H of the Drugs and Cosmetics Act, requiring a prescription for its dispensation. The National Pharmaceutical Pricing Authority (NPPA) has not set a ceiling price for mefloquine, allowing market-driven pricing. Exporters must obtain a No Objection Certificate (NOC) from the Directorate General of Foreign Trade (DGFT) for the export of pharmaceuticals, ensuring compliance with national regulations.

The primary patents for mefloquine have expired, leading to the availability of generic versions in various markets. However, the absence of approved ANDAs in the U.S. indicates limited generic competition in that market.

In December 2025, the EMA updated the product information for mefloquine-containing medicines, emphasizing the need for monitoring neuropsychiatric side effects. (ema.europa.eu) In November 2025, the UK Ministry of Defence reported a continued decline in mefloquine prescriptions among armed forces personnel, reflecting a shift towards alternative antimalarial therapies. (gov.uk)

These developments highlight the evolving regulatory landscape and the importance of staying informed about policy changes affecting mefloquine's market dynamics.

Mefloquine, an antimalarial medication, is primarily produced in India, which has a robust pharmaceutical manufacturing sector. However, India's production of Active Pharmaceutical Ingredients (APIs) like Mefloquine is heavily reliant on Key Starting Materials (KSMs) imported from China. According to the U.S. Pharmacopeia's Medicine Supply Map, 41% of KSMs used in U.S.-approved APIs are solely sourced from China, while 16% come exclusively from India. This dependency exposes the supply chain to risks associated with geopolitical tensions, trade disputes, and regulatory changes in China.

In recent years, environmental regulations in China have led to the shutdown of several chemical manufacturing plants, causing disruptions in the supply of KSMs. For instance, in July 2018, Chinese authorities enforced stringent pollution controls, resulting in the closure of numerous factories and subsequent supply chain interruptions for Indian pharmaceutical companies. Such events underscore the vulnerability of India's pharmaceutical industry to external factors affecting KSM availability.

Our proprietary trade data indicates that between 2022 and 2026, Mefloquine exports from India totaled $2.4 million USD across 265 shipments, involving 75 active exporters and reaching 56 destination countries. Notably, the top five exporters accounted for 69.4% of the total export value, with CIPLA LIMITED alone contributing 57.3% ($1.4 million USD). This high supplier concentration poses a significant single-source risk; any operational disruptions at CIPLA LIMITED could substantially impact global Mefloquine supply.

To mitigate such risks, the Indian government has implemented the Production Linked Incentive (PLI) scheme, aiming to bolster domestic API and KSM production and reduce reliance on imports. In October 2024, two greenfield plants were inaugurated under this scheme to manufacture critical molecules like Penicillin G and 6-Aminopenicillanic Acid (6-APA), essential for various antibiotics. While these initiatives are steps toward self-reliance, their impact on diversifying Mefloquine's supplier base remains to be seen.

Geopolitical tensions and shipping disruptions significantly affect pharmaceutical supply chains. In March 2026, the Strait of Hormuz crisis led to a sharp decline in maritime transit, with tanker traffic dropping by approximately 70% and over 150 ships anchoring outside the strait to avoid risks. This disruption affected about 20% of the world's daily oil supply and significant volumes of liquefied natural gas (LNG), prompting major shipping firms to suspend operations in the area. Such events can delay shipments of APIs and KSMs, leading to production halts and potential drug shortages.

Additionally, the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have issued alerts regarding drug shortages stemming from supply chain disruptions. These shortages highlight the fragility of global pharmaceutical supply chains and the need for robust risk management strategies.

• Diversify Supplier Base: Engage with multiple suppliers across different regions to reduce dependency on a single source for APIs and KSMs.

• Enhance Domestic Production: Invest in local manufacturing capabilities for critical APIs and KSMs to decrease reliance on imports.

• Strengthen Supply Chain Visibility: Implement advanced tracking systems to monitor the movement of raw materials and finished products, enabling proactive responses to potential disruptions.

• Develop Strategic Reserves: Establish stockpiles of essential APIs and KSMs to buffer against short-term supply interruptions.

• Collaborate with Regulatory Bodies: Work closely with agencies like the FDA and EMA to stay informed about potential shortages and regulatory changes that may impact supply chains.

RISK_LEVEL: HIGH